Praetorian Wealth Management’s Telomir Pharmaceuticals TELO Stock Holding History

Praetorian Wealth Management’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.6K	Hold	20,000	–	–	﹤0.01%	84
2026 Q1	$26.6K	Buy	20,000 +10,000	+100%	+$12.8K	0.01%	77
2025 Q4	$13.3K	Sell	10,000 -10,000	-50%	-$14.4K	﹤0.01%	74
2025 Q3	$27.8K	Buy	+20,000	New	+$30.2K	0.01%	64

Other funds holding TELO

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

Praetorian Wealth Management's TELO Position: Q2 2026 in Review

Praetorian Wealth Management held its Telomir Pharmaceuticals (TELO) position steady in Q2 2026 at 20,000 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #84.

Praetorian Wealth Management first reported a position in TELO in Q3 2025 and has held it in 4 quarters since. The position peaked at $27.8K in Q3 2025. 3 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

Praetorian Wealth Management held 20,000 shares of Telomir Pharmaceuticals worth $25.6K as of Q2 2026.
Praetorian Wealth Management left its Telomir Pharmaceuticals share count unchanged in Q2 2026.
Telomir Pharmaceuticals made up ﹤0.01% of Praetorian Wealth Management's portfolio in Q2 2026, its #84 holding.
Praetorian Wealth Management first reported a position in Telomir Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
Praetorian Wealth Management's Telomir Pharmaceuticals position peaked at $27.8K in Q3 2025.
3 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Praetorian Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.